

Beam Therapeutics Inc. (BEAM)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001745999

Beam Therapeutics Inc.

BEAM; healthcare

Grade

C/D

on the C/D boundary of 371 graded peers
percentile 61.4; sampling error 2.5 points; lower is stronger

Rank

228 of 371

Profitability

E

percentile 95.4

Solvency

A/B

percentile 17.7

Growth and financing

B/C

percentile 42.2

Reliability

0.91 AUC

filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025

Peer failure rate

1.01% a year

Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

\$591M to \$2.67B assets

total assets \$1.5B

Standard universe

inside

revenue above \$1M and assets above \$10M

Warnings

none active

not computable: fortress balance sheet

Inputs computable

7 of 14

Graded from

filings received through Feb 24, 2026

227 days before the rescans; latest periodic filing 10-Q received Aug 4, 2026

Last close

\$24.59

2026-10-08; market equity \$2.5B

Price used in grade

None




C/D, the tortoise

on the C/D boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D from Aug 21, 2026, C/D from Sep 26, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities. Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision

genetic medicines that target a single base in the genome without making a double-stranded break in the DNA.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 95.4						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		20.5%	(6.6%)	95.4	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 17.7						
Twelve-month failure probability		0.04%	0.07%	25.1	248	2026-06-30
Altman Z double-prime		5.19	(0.31)	18.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		13.09x	2.96x	9.9	839	2025-12-31
Growth and financing, sleeve percentile 42.2						
Revenue growth, three-year compound		31.9%	10.0%	20.3	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		3.4%	2.1%	44.2	704	2025-12-31
Net share issuance, one year		21.7%	2.5%	62.1	634	2026-02-17

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
223	Labcorp Holdings Inc. (LH)	60.0	C/D	
224	Perspective Therapeutics, Inc. (CATX)	60.3	C/D	dilution, fortress balance sheet
225	ARS Pharmaceuticals, Inc. (SPRY)	60.5	C/D	short runway
226	Twist Bioscience Corp. (TWST)	60.8	C/D	fortress balance sheet
227	Teva Pharmaceutical Industries Ltd. (TEVA)	61.1	C/D	
228	Beam Therapeutics Inc. (BEAM) <	61.4	C/D	
229	Akebia Therapeutics, Inc. (AKBA)	61.6	C/D	fortress balance sheet
230	Mannkind Corp. (MNKD)	61.9	C/D	
231	Strata Critical Medical, Inc. (SRTA)	62.2	C/D	short runway, fortress balance sheet
232	Embecta Corp. (EMBC)	62.4	C/D	late filer
233	Biogen Inc. (BIIB)	62.7	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	21.3%	8.0%	60
Distance from 52-week high	(35.1%)	(31.4%)	44
EBIT to enterprise value	(15.8%)	(1.5%)	26
Free cash flow yield	(14.2%)	(1.0%)	27
Book value to price	0.42	0.28	63
Sales to price	0.05	0.31	18
Composite equity issuance, five years	50.4%	20.3%	66
Relative strength against the sector, log excess return	(0.02)	(0.14)	60

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	

Cash and equivalents	\$219.8M
Operating cash flow, four quarters	-\$359.4M
Months of runway	7.3
Days since last periodic filing	66 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	\$43.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$80.0M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$345.1M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
3	assets	us-gaap:Assets	\$1.5B	2025-12-31	2026-02-24	10-K	0001193125-26-065194
4	assets	us-gaap:Assets	\$1.1B	2024-12-31	2026-02-24	10-K	0001193125-26-065194
5	current assets	us-gaap:AssetsCurrent	\$1.3B	2025-12-31	2026-02-24	10-K	0001193125-26-065194
6	current liabilities	us-gaap:LiabilitiesCurrent	\$96.9M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.6B	2025-12-31	2026-02-24	10-K	0001193125-26-065194
8	operating income	us-gaap:OperatingIncomeLoss	-\$383.7M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
9	book equity	us-gaap:StockholdersEquity	\$1.2B	2025-12-31	2026-02-24	10-K	0001193125-26-065194
10	liabilities	us-gaap:Liabilities	\$242.8M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$139.7M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$63.5M	2024-12-31	2026-02-24	10-K	0001193125-26-065194
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$377.7M	2023-12-31	2026-02-24	10-K	0001193125-26-065194
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$60.9M	2022-12-31	2025-02-25	10-K	0000950170-25-026076
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$14.9M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$347.2M	2024-12-31	2026-02-24	10-K	0001193125-26-065194
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.9M	2024-12-31	2026-02-24	10-K	0001193125-26-065194
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$149.2M	2023-12-31	2026-02-24	10-K	0001193125-26-065194
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$33.7M	2023-12-31	2026-02-24	10-K	0001193125-26-065194
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$22.5M	2022-12-31	2025-02-25	10-K	0000950170-25-026076
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$49.0M	2022-12-31	2025-02-25	10-K	0000950170-25-026076
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$22.3M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
23	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$80.0M	2025-12-31	2026-02-24	10-K	0001193125-26-065194
24	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-02-24	10-K	0001193125-26-065194
25	current assets	us-gaap:AssetsCurrent	\$878.1M	2024-12-31	2026-02-24	10-K	0001193125-26-065194
26	current liabilities	us-gaap:LiabilitiesCurrent	\$182.1M	2024-12-31	2026-02-24	10-K	0001193125-26-065194
27	assets	us-gaap:Assets	\$1.5B	2023-12-31	2025-02-25	10-K	0000950170-25-026076
28	assets	us-gaap:Assets	\$1.3B	2022-12-31	2024-02-27	10-K	0000950170-24-020622
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	101,856,245	2026-02-17	2026-02-24	10-K	0001193125-26-065194
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	83,688,295	2025-02-18	2025-02-25	10-K	0000950170-25-026076